Tamura Manabu, Shikina Takashi, Morihana Tetsuo, Hayama Masaki, Kajimoto Osami, Sakamoto Akane, Kajimoto Yoshitaka, Watanabe Osamu, Nonaka Chiaki, Shida Kan, Nanno Masanobu
Department of Otolaryngology and Sensory Organ Surgery, Osaka University School of Medicine, Osaka, Japan.
Int Arch Allergy Immunol. 2007;143(1):75-82. doi: 10.1159/000098318. Epub 2006 Dec 29.
Lactobacillus casei strain Shirota (LcS) has been found to exert antiallergic effects in animal experiments, but there is little information about its clinical effects in human patients with allergy.
We performed a randomized double-blind, placebo-controlled study to investigate the effects of LcS in patients with allergic rhinitis triggered by Japanese cedar pollen (JCP). Participants were asked to drink fermented milk containing LcS (LcS group) or placebo (control group) for 8 weeks. Clinical symptoms and immunological parameters were compared between the two groups.
Symptom-medication scores (SMS) worsened in accordance with the increase in the amount of scattered JCP. In terms of the nasal and ocular SMS, there was no significant difference between the LcS group and the placebo group during the ingestion period. In the subgroup of patients with moderate-to-severe nasal symptom scores before starting the ingestion of test samples, supplementation with LcS tended to reduce nasal SMS.
These results indicate that fermented milk containing LcS does not prevent allergic symptoms in patients sensitive to JCP, but may delay the occurrence of allergic symptoms in patients with moderate-to-severe nasal symptom scores.
在动物实验中发现干酪乳杆菌代田株（LcS）具有抗过敏作用，但关于其对人类过敏患者的临床效果的信息较少。
我们进行了一项随机双盲、安慰剂对照研究，以调查LcS对日本雪松花粉（JCP）引发的过敏性鼻炎患者的影响。参与者被要求饮用含LcS的发酵乳（LcS组）或安慰剂（对照组），持续8周。比较两组的临床症状和免疫参数。
症状药物评分（SMS）随着JCP飘散量的增加而恶化。在摄入期间，就鼻部和眼部SMS而言，LcS组和安慰剂组之间没有显著差异。在开始摄入测试样品前鼻部症状评分为中重度的患者亚组中，补充LcS有降低鼻部SMS的趋势。
这些结果表明，含LcS的发酵乳不能预防对JCP敏感患者的过敏症状，但可能会延缓鼻部症状评分为中重度患者的过敏症状出现。
